Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 3/20 | 0.32 |
| ▸ | CDK4 | P11802 | 3/20 | 0.32 |
| ▸ | CCND1 | P24385 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938911 | 0.79 | PPARA (0.37) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL2250305 | 0.78 | CCNE2 (0.39) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4933608 | 0.77 | CDK4 (0.34) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4930597 | 0.77 | CDK2 (0.34) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL3289678 | 0.66 | KMT2A (0.35) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL31194557 | 0.65 | CDK4 (0.33) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL26871203 | 0.61 | CCNT1 (0.36) | CDK4CCND1CCNE1CDK2GRM2 | |
| SCHEMBL6436636 | 0.61 | PDE4B (0.37) | LRRK2 | |
| SCHEMBL4934098 | 0.60 | PTGDR2 (0.31) | — | |
| SCHEMBL26871183 | 0.59 | KDM4E (0.36) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | CCNE2 2340/4885CDK4 290/4885CCND1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.